Malignant Hypercalcemia
Malignant Hypercalcemia is a topic covered in the Washington Manual of Medical Therapeutics.
To view the entire topic, please log in or purchase a subscription.
The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Explore these free sample topics:
-- The first section of this topic is shown below --
- Malignant hypercalcemia is a common paraneoplastic syndrome and occurs in nearly 10%–20% of cancer patients.
- A serum total calcium level of >10.5 g/dL is generally considered elevated. Measuring ionized calcium can be necessary and helpful in patients with abnormal serum albumin levels.
- Osteolysis and humoral hypercalcemia through tumor production of parathyroid hormone (PTH), PTH-related protein (PTHrP), or vitamin D analogues are the predominant mechanisms of hypercalcemia.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
- Malignant hypercalcemia is a common paraneoplastic syndrome and occurs in nearly 10%–20% of cancer patients.
- A serum total calcium level of >10.5 g/dL is generally considered elevated. Measuring ionized calcium can be necessary and helpful in patients with abnormal serum albumin levels.
- Osteolysis and humoral hypercalcemia through tumor production of parathyroid hormone (PTH), PTH-related protein (PTHrP), or vitamin D analogues are the predominant mechanisms of hypercalcemia.
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2022 Unbound Medicine, Inc. All rights reserved